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Abstract
Background: The Pediatric Quality of Life Inventory™ (PedsQL™) is a widely-used modular instrument for measuring 
health-related quality of life in children aged 2 to 18 years. The PedsQL™ Brain Tumor Module is comprised of six scales: 
Cognitive Problems, Pain and Hurt, Movement and Balance, Procedural Anxiety, Nausea, and Worry. In the present 
study, we developed the Japanese version of the PedsQL™ Brain Tumor Module and investigated its feasibility, 
reliability, and validity among Japanese children and their parents.
Methods: Translation equivalence and content validity were verified using the standard back-translation method and 
cognitive debriefing tests. Participants were recruited from 6 hospitals in Japan and the Children's Cancer Association 
of Japan, and questionnaires were completed by 137 children with brain tumors and 166 parents. Feasibility of the 
questionnaire was determined based on the amount of time required to complete the form and the percentage of 
missing values. Internal consistency was assessed using Cronbach's coefficient alpha. Test-retest reliability was assessed 
by retesting 22 children and 27 parents. Factorial validity was verified by exploratory factor analyses. Known-groups 
validity was described with regard to whole brain irradiation, developmental impairment, infratentorial tumors, paresis, 
and concurrent chemotherapy. Convergent and discriminant validity were determined using Generic Core Scales and 
State-Trait Anxiety Inventory for children.
Results: Internal consistency was relatively high for all scales (Cronbach's coefficient alpha > 0.70) except the Pain and 
Hurt scale for the child-report, and sufficient test-retest reliability was demonstrated for all scales (intraclass correlation 
coefficient = 0.45-0.95). Factorial validity was supported through exploratory factor analysis (factor-item correlation = 
0.33-0.96 for children, 0.55-1.00 for parents). Evaluation of known-groups validity confirmed that the Cognitive 
Problems scale was sensitive for developmental impairment, the Movement and Balance scale for infratentorial tumors 
or paresis, and the Nausea scale for a patient currently undergoing chemotherapy. Convergent and discriminant 
validity with the PedsQL™ Generic Core Scales and State-Trait Anxiety Inventory for children were acceptable.
Conclusions: The Japanese version of the PedsQL™ Brain Tumor Module is suitable for assessing health-related quality 
of life in children with brain tumors in clinical trials and research studies.
Background
Five-year survival rates for pediatric brain tumor patients
are approaching 70% [1], and with this increasing survival
rate comes the challenge of improving these patients'
overall quality of life. Children undergoing treatment for
these tumors often show several typical symptoms, such
as pain, nausea, and a lack of energy [2]. Further, even
after treatment has ended, consequences to the original
tumor or this therapy remain, including neurological and
endocrinological problems [3-5]. Among long-term sur-
vivors, cognitive problems and difficulties with psychoso-
cial adjustment have been reported years after treatment
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[3-8]. Other studies have also noted further evidence sup-
porting the notion that children with brain tumors expe-
rience generally lower health status and quality of life
than children afflicted with other malignant diseases at
all stages of their disease and recovery [9,10].
We can thus determine from these previous studies that
indices for endpoints secondary to survival are necessary
to improve quality of life among these patients, and to
this end, clinicians and researchers have turned their
focus to health-related quality of life (HRQOL) [11].
HRQOL is a continuous concept influenced by a person's
objective assessments of function or health status as well
as subjective perceptions of their personal health [12].
The domain set for HRQOL, such as physical, emotional,
and cognitive domains, varies according to an individual's
characteristics, such as age and disease. Several widely-
used measurements specific to assessing HRQOL in
patients with brain tumors have been developed already,
including Functional Assessment of Cancer Therapy -
Brain Subscale [13] and European Organisation for
Research and Treatment Center Quality of Life Question-
naire - Brain Caner Module [14], but these methods are
not suitable for use on children. To measure HRQOL
among children with brain tumors, we have used the
Pediatric Quality of Life Inventory™ (PedsQL™) Generic
Core Scales [15], which contain general domains but no
brain tumor-specific domains. Taking into account this
need for a more appropriate measurement, the PedsQL™
Brain Tumor Module [16] was developed as a PedsQL™
disease-specific module.
The PedsQL™ is a widely-used measurement of
HRQOL in children aged 2-18 years [15]. Reports are
conducted bilaterally; children aged 5-18 are asked to
evaluate their own HRQOL (child-report) and the par-
ents of children aged 2-18 are asked to evaluate their
child's HRQOL (parent-report). The PedsQL™ was
designed under a modular-approach [17] to cover both
generic and disease-specific domains. The PedsQL™
Brain Tumor Module was developed through focus
groups involving healthcare providers, children, and par-
ents; cognitive interviews; pre-testing; and field-testing
[16]. We determined the PedsQL™ Brain Tumor Module
to be highly appropriate for use in assessing HRQOL in
children with brain tumors, who often suffer from dys-
function of higher cognitive abilities and visual and phys-
ical impairment [3,4], for three reasons. First, the module
contains only 24 items, a number far fewer than other
scales, thereby reducing the time required to complete
the questionnaire. This relatively short questionnaire is
ideal for administration to children, given their short
attention spans when compared to adults. Second, the
PedsQL™ protocol permits interviewer administration for
children who have difficulty completing self-adminis-
tered questionnaires [16,18], ideal for children with visual
or motor impairments. Third, the module features sev-
eral formats aimed at children across several age groups,
including questionnaires for children aged 5-7 (young
child), 8-12 (child), and 13-18 (adolescent) years. In com-
parison, the parent-report includes questionnaires for
parents of children aged 2-4 (toddler), 5-7, 8-12, and 13-
18 years. Although the format varies according to lifestyle
and cognitive development level, the measured content
and concepts are the same for all ages. This relatively
wide age-range and comparability across age ranges
allows us to simultaneously examine results across multi-
ple age groups and longitudinally examine a specific-age
group for a relatively long period of time.
In the present study, to facilitate the sharing of data
across international borders, we developed the Japanese
version of the PedsQL™ Brain Tumor Module and investi-
gated its feasibility, reliability, and validity. Given the wide
biological diversity exhibited by brain tumors, the num-
ber of patients available to participate in trials is invari-
ably limited by the paucity of homogeneous groups in a
single country [19]. Clinical trials and epidemiological
studies on an international scale are therefore of the
utmost importance, requiring feasible, reliable, and valid
global indices.
Methods
Scale development
Permission was obtained from the rights holder, Dr.
James W. Varni (JWV), to translate the PedsQL™ Brain
Tumor Module into Japanese using a preassigned transla-
tion procedure [20]. Two Japanese translators proficient
in English produced forward translations independent of
one another. These forward translations were then dis-
cussed among the authors and translators, all of whom
agreed on a single, reconciled version which was a con-
ceptually equivalent translation of the original English
version and written in easily understood language. An
English translator proficient in Japanese and blinded to
the original English version then translated this recon-
ciled version back into English. After comparing the
back-translated and original versions and making minor
amendments to the reconciled version, we produced a
pilot questionnaire.
Eight children with brain tumors participated in pilot
testing along with their parents. A researcher (IS or AH)
measured the time taken to complete the questionnaire.
On completing the questionnaire, the researcher inter-
viewed each child and his or her parent, and the thought
processes used in answering the questionnaire were
deduced by cognitive interviewing [21]. A final version of
the Japanese version of the PedsQL™ Brain Tumor Mod-
ule was produced after revising the pilot version using
data obtained during pilot testing. JWV reviewed theSato et al. Health and Quality of Life Outcomes 2010, 8:38
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conceptual and linguistic equivalence between the final
Japanese version and the original English version.
Study population
We recruited children with brain tumors and their par-
ents from six hospitals across Japan and from the Chil-
dren's Cancer Association of Japan (CCAJ), a non-profit
organization established in 1968 which supports children
with cancer and their families. Participants were
recruited from September to December 2008. With
regard to inclusion criteria, a child was included if he or
she was aged 5 to 18 years, while the parent was included
if his or her child was aged 2 to 18 years (age range cov-
ered by the PedsQL™). Families were included in the study
if at least one month had passed since the child's brain
tumor diagnosis. With regard to exclusion criteria, fami-
lies were excluded from the study if hospital doctors or
social workers of the CCAJ determined the family to be
unsuitable for participating in the study due to finding
the subject of brain tumors too painful to discuss.
Procedure
Researchers presented this study to 101 children and 122
parents at the participating hospitals both orally and in
writing. Of these, 98 children and 120 parents elected to
participate, providing informed consent or assent. At
CCAJ, the study was described in writing to all families
invited to a meeting regarding brain tumors. Of 55
responding families, 45 children and 52 parents provided
informed consent or assent. Two of the families were
bereaved, one had an adult survivor, six children were
aged two to four years, and one child did not provide
informed consent. In total, questionnaires were distrib-
uted to 143 children and 172 parents.
Child-report questionnaires were self- or interviewer-
administered to participants. When providing informed
consent, parents determined whether their child was able
to self-administer the questionnaire. In accordance with
the PedsQL™ administration guidelines, children aged 5-7
years or otherwise determined to be incapable of self-
administration were administered the questionnaire by
either a researcher or their parents reading the instruc-
tions and each item [15,16,18]. At the same time, parent-
report questionnaires were self-administered to partici-
pants.
After administration, questionnaires were collected
from 138 children and 167 parents, with 5 children and 5
parents not returning their questionnaires. One child and
one parent were unable to answer the questionnaire
(respective reasons are described in the Results section),
and thus answers from 137 children and 166 parents were
ultimately analyzed.
Retest reliability was assessed at the two hospitals
located nearest to our study group's agency, and the
details of the retest were explained to all 27 children and
31 parents enrolled in the initial study orally and in writ-
ing following completion of the initial questionnaire.
After undergoing assessment by their attending physi-
cian, all children were determined to be stable. The same
parents who completed the initial questionnaire were
asked to complete the retest. In total, 24 children and 29
parents provided informed consent or assent. Partici-
pants were readministered the PedsQL™ Brain Tumor
Module between 7 and 28 days (median = 9.5) after com-
pletion of the initial questionnaire. At the same time, we
inquired into any changes in the child's physical condition
or lifestyle during this period. Retest reliability was evalu-
ated on exclusion of responses from either a child or a
parent which reported changes in the child's physical
condition or lifestyle during the period.
Measurements
The PedsQL™ Brain Tumor Module [16] is comprised of
six scales: Cognitive Problems (seven items), Pain and
Hurt (three items), Movement and Balance (three items),
Procedural Anxiety (three items), Nausea (five items),
and Worry (three items). The parent-report for toddlers
(ages 2-4) does not include the Cognitive Problems scale,
while the child- and parent-reports for young children
(ages 5-7) list only six items on the Cognitive Problems
scale.
Respondents are asked to describe the extent to which
each item has troubled them over the past seven days. For
the child-reports for ages 8-18 and all parent-reports, a 5-
point Likert response scale is used (0 = never [a problem];
1 = almost never; 2 = sometimes; 3 = often; 4 = almost
always). For the child-report for children ages 5-7, a 3-
point face response scale is used to aid participants in
understanding the concept of rating scales. Items are
reverse-scored and linearly transformed to a 0-100 scale,
w i t h  h i g h e r  s c o r e s  i n d i c a t i n g  a  b e t t e r  H R Q O L .  T o
account for missing data, scale scores are computed as
the sum of the items divided by the number of items
answered. If more than 50% of the items are missing or
incomplete, the scale score is not computed. JWV's origi-
nal version has acceptable construct validity and internal
consistency (Cronbach's coefficient alpha [22] = 0.76-
0.92).
The PedsQL™ Generic Core Scales [15] has four scales:
Physical Functioning (eight items), Emotional Function-
ing (five items), Social Functioning (five items), and
School Functioning (five items). The format, instructions,
response scale, and scoring method are identical to the
PedsQL™ Brain Tumor Module. The Japanese version of
the PedsQL™ Generic Core Scales was developed by
Kobayashi et al [23]. Internal consistencies for the Physi-
cal, Emotional, Social, and School Functioning scales for
the child- and parent-reports in the current study wereSato et al. Health and Quality of Life Outcomes 2010, 8:38
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0.84 and 0.92, 0.76 and 0.82, 0.74 and 0.89, and 0.73 and
0.77, respectively.
The State-Trait Anxiety Inventory for Children
(STAIC) [24] is comprised of two scales: State Anxiety
(20 items) and Trait Anxiety (20 items). Each scale is
scored for children aged 8 or over on three levels of self-
reported anxiety intensity, with a sum score between 20
and 60 and higher scores indicating increased anxiety.
The Japanese version was developed by Soga [25]. Inter-
nal consistencies for the State and Trait Anxiety scales in
the current study were 0.89 and 0.89, respectively.
Parents were also asked to describe their child's charac-
teristics, namely the child's age, sex, tumor pathology,
tumor location, age at diagnosis, experience with treat-
ment, medical history, and existing complications. Par-
ents were also questioned regarding what they believed
their economic status to be, their age, their biological
relationship to their child, and their academic back-
ground.
Statistical analyses
All analyses were performed using SPSS software, version
12.0J (SPSS, Inc., Chicago, Illinois, USA) and the level of
significance set at 0.05. Missing values were considered
by pair-wise case deletion. Score distributions for the Jap-
anese version of the PedsQL™ Brain Tumor Module were
summarized as mean, standard deviation, median, mini-
mum and maximum scores, and percentages of floor (0)
and ceiling (100) scores. The concordance between child-
and parent-reports was determined using intraclass cor-
relation coefficients (ICC) in the two-way mixed effects
model [26].
Feasibility was determined based on the amount of
time required to complete the pilot questionnaire and the
percentage of missing values. Independence of easily
missed items was tested by Cochran's Q test. Reliability
was tested by internal consistency and retest reliability.
Good internal consistency was defined as a Cronbach's
coefficient alpha value exceeding 0.70. To determine
retest reliability, the ICC between the initial test and
retest scores in the one-way random effects model was
examined, with an ICC value of 0.40 representing moder-
ate, 0.60 good, and 0.80 high agreement.
Validity was tested by factorial validity, known-groups
validity, and convergent and discriminant validity.
Exploratory factor analyses using the principal factor
method and the promax rotation were conducted on the
24 items. To describe known-groups validity, 95% confi-
dence intervals between groups were calculated. We ini-
tially predicted that the Cognitive Problems scale scores
would be low among children who had received whole
brain irradiation and those with developmental impair-
ment (mental retardation or learning disability), that the
Movement and Balance scale scores would be low among
children with infratentorial tumor and those with paresis,
and that the Nausea scale score would be low among chil-
dren currently undergoing chemotherapy.
Convergent and discriminant validity was examined by
correlating the scales of the Japanese version of the Ped-
sQL™ Brain Tumor Module with the theoretically-pre-
dicted scales of the PedsQL™ Generic Core Scales and
STAIC. Pearson's product-moment correlation coeffi-
cient was calculated and corrected for attenuation [27].
We initially predicted that the Cognitive Problems scale
would correlate relatively with the School Functioning
scale, the Movement and Balance scale with the Physical
Functioning scale, the Procedural Anxiety scale with the
Emotional Functioning and the Trait Anxiety scales, and
the Worry scale with the Emotional Functioning scale.
As our study was the first to give standard score distri-
butions for the PedsQL™ Brain Tumor Module in Japan,
we did not set ceilings on the sample size. Instead, we set
a ceiling of four months on the study duration. Power
analysis using the findings from the original English ver-
sion [16] demonstrated that the minimum requisite sam-
ple size was 85 subjects, allowing for a specificity of 0.95
and a power of 0.8 for medium correlation (0.3) in the
examination of convergent and discriminant validity. For
the retest, the sample size was set at 22 subjects to
achieve a specificity of 0.95 and a power of 0.8, allowing
for observation of ICC values of 0.5 or greater for ICC
parameters of 0.8 [28].
Ethical considerations
This study was approved by the review boards of all seven
participating institutions. In consideration of the Japa-
nese sociocultural environment, we avoided using the
terms "cancer" or "tumor" with the children, using alter-
nate terms in introductory writings and questionnaires.
For participation of children aged 13 or over, informed
consent from both children and parents was required. For
participation of children aged 12 or under, informed
assent from the child and informed consent from the par-
ents was required.
Results
Sample characteristics
The median age of the children was 10.0 years (Table 1).
The sample was heterogeneous with respect to tumor
pathology and treatment experiences, and median time
from diagnosis was 2.4 years. Sixty children (36.1%) had
undergone whole brain irradiation at a median age of 7.0
years old, a median of 2.8 years before answering the
questionnaire. Sixty parents (36.6%) regarded their own
economic status and life as "affluent", in that they were
financially secure and comfortable in their daily living.Sato et al. Health and Quality of Life Outcomes 2010, 8:38
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Table 1: Subject Characteristics
Number of respondents 
(n)
% of total Median
(years)
Range
(years)
Age 166 100 10.0 2 - 18
Sex
Male 91 55.2
Female 74 44.8
Tumor Pathology
Embryonal tumors 47 29.0
Germ cell tumors 36 22.2
High-grade glioma 25 15.4
Low-grade glioma 39 24.1
Other 15 9.3
Time from diagnosis 165 99.4 2.4 0.1 - 16.8
Period
Inpatients 42 25.3
Outpatients on 
treatment
23 13.9
Outpatients with 
scheduled follow-up
99 59.6
Outpatients without 
scheduled follow-up
21 . 2
Medical history
Cancer 3 1.8
Heart disease 4 2.4
Neurofibromatosis 2 1.2
Treatment received
None 5 3.0
Surgery (S) 23 13.9
Radiation (R) 1 0.6
Chemotherapy (C) 4 2.4
S+R 16 9.6
S+C 24 14.5
R+C 5 3.0
S+R+C 88 53.0
Have experience with stem cell transplantation
Yes 17 10.2
No 149 89.8
Have experience with whole brain irradiation
Yes 60 36.1
No 106 63.9Sato et al. Health and Quality of Life Outcomes 2010, 8:38
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Scale descriptions
Values for all scales except the Pain and Hurt scale fell in
the possible range of 0 to 100 (Table 2). For both child-
and parent-reports, ranges of values for the Pain and Hurt
scale were relatively narrow and placed higher. Over half
of surveyed children (52.2%) reported the maximum
score possible on the Movement and Balance Scale. Scale
scores for all scales were consistently higher for the child-
reports than for the parent-reports. Comparatively good
concordance was seen between the child- and parent-
reports for the Movement and Balance, Procedural Anxi-
ety, and Nausea scales. In contrast, relatively poor con-
cordance was seen between the two reports for the
Worry scale.
Feasibility
With regard to time required to complete the pilot ques-
tionnaire, 4-11 minutes was required for completion of
the child-report and 2-6 minutes for the parent-report,
with 1.6% and 0.8% of values missing, respectively. The
percentage of missing values for each item was indepen-
dent (P = 0.84 for child-report, 1.00 for parent-report).
One child with mental retardation, diagnosed as 2-4
developmental years old, was unable to answer the child-
r e p o r t  q u e s t i o n n a i r e ,  a l t h o u g h  h i s  p a r e n t  w a s  a b l e  t o
answer the parent-report. One parent of a bedridden
child unable to indicate his intentions could not answer
the parent-report questionnaire.
Of the children at an eligible age to self-administer the
questionnaire, 19 (17%) were interviewer-administered (1
with mental retardation, 2 with difficulty understanding
the questionnaire, 1 with difficulty sustaining attention, 2
with difficulty reading, 7 with optical impairment, 2 with
difficulty writing by hand, 2 with both optical impairment
and difficulty writing by hand, and 2 experiencing
fatigue). All 19 were able to answer the self-report under
interviewer-administration.
Reliability
All scales except the Pain and Hurt scale for the child-
report indicated good internal consistency (Cronbach's
coefficient alpha = 0.50) (Table 3). On examination by
age-appropriate format, good internal consistency was
not observed in the Nausea scale for the young children
(5-7 years old) child-report and in the Worry scale for
Age at whole brain 
irradiation
60 36.1 7.0 0 - 18
Time since whole brain 
irradiation
60 36.1 2.8 0.0 - 14.8
Subjective opinion regarding own economic status and life
Affluent 60 36.6
Not affluent 104 63.4
Relationship of parent to child
Mother 153 92.2
Father 10 6.0
Grandmother 2 1.2
Grandfather 1 0.6
Academic background of parents
Junior high school 3 1.8
High school 64 39.3
Vocational school 28 17.2
Junior college 29 17.8
University 
(undergraduate)
36 22.1
University (graduate) 3 1.8
Total (n) = 166
Missing data were excluded.
Table 1: Subject Characteristics (Continued)Sato et al. Health and Quality of Life Outcomes 2010, 8:38
http://www.hqlo.com/content/8/1/38
Page 7 of 14
Table 2: Score distributions and child-parent relationships of the Japanese version of the PedsQL™ Brain Tumor Module
Number 
of 
patients 
(n)
Mean SD Median Minimum Floor
(%)
Maximum Ceiling
(%)
Differencea SD 95% CI ICC
Child-report
Cognitive 
Problems
137 69.6 21.9 71.4 0 1.5 100 10.2 5.2 22.5 1.43 9.02 0.49
Pain and 
Hurt
136 84.4 18.4 91.7 16.7 0.0 100 43.4 3.5 20.5 0.04 7.00 0.41
Movement 
and 
Balance
136 83.9 24.6 100.0 0 2.2 100 52.2 13.0 22.9 9.12 16.87 0.64
Procedural 
Anxiety
136 69.5 30.7 75.0 0 7.4 100 27.9 9.2 27.8 4.45 13.87 0.62
Nausea 136 85.9 21.3 95.0 0 0.7 100 48.5 2.3 19.1 -0.89 5.58 0.65
Worry 136 79.6 23.7 83.3 0 1.5 100 39.0 4.4 30.2 -0.75 9.51 0.18
Parent-report
Cognitive 
Problems
140 64.1 22.6 64.3 0 1.4 100 6.4
Pain and 
Hurt
165 81.5 19.7 83.3 25.0 0.0 100 41.2
Movement 
and 
Balance
166 70.4 29.3 75.0 0 3.6 100 31.9
Procedural 
Anxiety
164 57.2 34.4 58.3 0 13.4 100 21.3
Nausea 164 84.2 23.0 95.0 0 0.6 100 49.4
Worry 164 76.5 23.1 75.0 0 1.2 100 29.3
aparent report score subtracted from child report score
CI, confidence interval; ICC, intraclass correlation coefficient
both the child- and parent-reports for children (8-12
years old).
At the retest, two children and two parents answered
that the physical condition or lifestyle of the child had
changed since responding to the initial questionnaire. We
therefore analyzed the retest answers of the remaining 22
children and 27 parents. On comparison of characteris-
tics between the retest and non-retest samples using
Fisher's exact test or Student's t-test, observed tendencies
for the retest sample were that children were undergoing
treatment (n = 17 [61%]; P = 0.008), parents were not
mothers (n = 5 [18%]; P = 0.008), and parents were rela-
tively old (average age, 43.5 years old; P = 0.001). No ten-
dency was noted with regard to the initial scores of the
retest sample being higher or lower than those of the
non-retest sample. In the retest sample, each retest scale
score fell in the same range as initial test scale scores
(Table 3). The Pain and Hurt scale for the child-report
indicated moderate agreement, while the other scales
indicated good or high agreement.
Validity
Exploratory factor analyses produced six factors corre-
spondent to each scale (Table 4). Factor-item correlations
were between 0.33 and 0.96 in the child-report, and 0.55
and 1.00 in the parent-report.
With regard to known-group differences, the Cognitive
Problems scale was sensitive for developmental impair-
ment, the Movement and Balance scale was sensitive for
tumor location (supratentorial or infratentorial) and
paresis, and the Nausea scale was sensitive for a patient
currently undergoing chemotherapy (Table 5). The Cog-
nitive Problems scale was not completely sensitive for
having received whole brain irradiation, with a 95% confi-Sato et al. Health and Quality of Life Outcomes 2010, 8:38
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Table 3: Reliability of the Japanese version of the PedsQL™ Brain Tumor Module
Cronbach's coefficient alpha Retest reliability (n = 28)
Age group
Total 
(n = 166)
Toddler 
(n = 26)
Young child 
(n = 31)
Child 
(n = 56)
Adolescent 
(n = 53)
Change SD 95% CI ICC
Child-report
Cognitive 
Problems
0.83 - 0.73 0.80 0.85 -1.3 15.1 -7.8 5.3 0.67
Pain and 
Hurt
0.50 - 0.48 0.35 0.57 -1.5 17.3 -9.0 6.0 0.45
Movement 
and 
Balance
0.78 - 0.78 0.79 0.75 0.0 14.6 -6.3 6.3 0.77
Procedural 
Anxiety
0.82 - 0.75 0.85 0.85 1.4 29.3 -11.2 14.1 0.67
Nausea 0.84 - 0.62 0.82 0.93 2.8 18.6 -5.3 10.8 0.74
Worry 0.75 - 0.84 0.60 0.76 -4.3 19.8 -12.9 4.2 0.70
Parent-report
Cognitive 
Problems
0.92 - 0.89 0.90 0.93 1.3 13.6 -4.7 7.3 0.76
Pain and 
Hurt
0.80 0.92 0.77 0.81 0.74 -2.9 13.3 -8.3 2.5 0.82
Movement 
and 
Balance
0.91 0.84 0.89 0.89 0.93 1.6 11.3 -3.0 6.2 0.92
Procedural 
Anxiety
0.96 0.98 0.94 0.95 0.96 -3.7 21.1 -12.4 5.1 0.82
Nausea 0.93 0.86 0.87 0.93 0.94 -1.0 8.2 -4.3 2.4 0.95
Worry 0.86 0.86 0.93 0.69 0.88 -0.3 16.2 -6.9 6.2 0.74
CI, confidence interval; ICC, intraclass correlation coefficient
dence interval from -2.3 to 12.9 in the child-report and
from 0.8 to 16.0 in the parent-report.
With regard to presumed hypotheses of convergent and
discriminant validity, the Cognitive Problems scale corre-
lated better with the School Functioning scale than with
the other three scales, and the Movement and Balance
scale correlated better with the Physical Functioning
scale than with the other three scales (Table 6). The Pro-
cedural Anxiety scale correlated slightly better with the
Emotional Functioning scale than with the other three
scales, although the difference was trivial. The Procedural
Anxiety scale also negatively-correlated better with the
Trait Anxiety scale than with the State Anxiety scale and
the Worry scale correlated relatively-better with the
Emotional Functioning scale than with the other three
scales. With regard to scales that correlated particularly
well in the parent-report, the Cognitive Problems scale
correlated well with the School Functioning scale, Move-
ment and Balance scale correlated well with the Physical
Functioning scale, and the Procedural Anxiety and Worry
scales correlated relatively well with the Emotional Func-
tioning scale.
Discussion
In the present study, to facilitate the sharing of data
across international borders, we developed the Japanese
language version of the PedsQL™ Brain Tumor Module
and confirmed its feasibility, reliability, and validity. Our
fixed forward-backward translation procedure used to
develop the survey ensures that the Japanese version con-
forms to the original both conceptually and linguistically
while keeping the Japanese culture in mind.
As the participants in the development of the original
PedsQL™ Brain Tumor Module included no children with
movement or balance problems, providing essentially no
variability in responses to these items, the Movement andSato et al. Health and Quality of Life Outcomes 2010, 8:38
http://www.hqlo.com/content/8/1/38
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Table 4: Factorial validity of the Japanese version of the PedsQL™ Brain Tumor Module
Child-report Parent-report
(n = 137, 64% of the cumulative variance) (n = 166, 78% of the cumulative variance)
Cognitive Problems
It is hard for me to 
figure out what to 
do when 
something 
bothers me
0.01 0.45 -0.06 0.15 0.06 0.15 0.60 -0.13 0.11 0.18 -0.01 0.08
I have trouble 
solving math 
problems
-0.01 0.54 0.25 -0.05 -0.05 -0.21 0.75 0.02 0.06 -0.05 -0.03 0.05
I have trouble 
writing school 
papers or reports
0.05 0.82 -0.02 0.06 -0.02 -0.25 0.79 -0.01 0.01 0.08 0.06 -0.13
It is hard for me to 
pay attention to 
things
-0.08 0.63 -0.07 -0.17 0.14 0.31 0.81 0.11 -0.09 -0.11 0.03 0.00
It is hard for me to 
remember what I 
read
0.04 0.68 -0.04 -0.09 0.13 0.18 0.88 0.04 -0.02 -0.03 -0.02 -0.04
It is hard for me to 
learn new things
-0.01 0.65 0.10 0.14 -0.21 -0.01 0.85 0.04 -0.09 0.01 -0.06 -0.01
I get mixed up 
easily
0.03 0.40 -0.07 0.27 -0.06 0.13 0.67 -0.11 0.09 0.03 0.07 0.11
Pain and Hurt
I ache or hurt in 
my joints and/or 
muscles
-0.10 -0.06 -0.02 0.15 -0.05 0.77 -0.03 -0.05 0.01 0.05 0.06 0.82
I hurt a lot 0.23 0.16 0.11 -0.03 -0.11 0.39 -0.01 -0.01 0.04 -0.02 -0.03 0.94
I get headaches -0.04 0.03 -0.08 -0.13 0.05 0.38 0.05 0.14 -0.12 -0.04 -0.03 0.55
Movement and 
Balance
It is hard for me to 
keep my balance
-0.01 0.06 -0.05 0.52 0.20 -0.13 0.01 -0.03 0.08 0.81 0.11 -0.04
It is hard for me to 
use my legs
0.01 -0.05 0.10 0.85 -0.08 0.06 -0.01 0.01 -0.05 1.00 -0.06 0.01
It is hard for me to 
use my hands
0.00 0.05 -0.09 0.87 0.11 -0.05 0.03 0.06 -0.06 0.83 -0.05 0.01
Procedural Anxiety
Needle sticks (i.e. 
injections, blood 
tests, IVs) hurt me
0.02 0.01 0.72 -0.14 0.11 -0.03 -0.04 0.01 0.89 0.04 0.02 0.03
I get scared when 
I have to have 
blood tests
-0.11 0.00 0.74 0.12 0.13 -0.13 0.02 0.04 0.95 -0.04 0.00 -0.06
I get scared about 
having needle 
sticks (i.e. 
injections, blood 
tests, IVs)
-0.03 0.10 0.89 -0.04 -0.06 0.05 0.01 0.01 0.98 -0.03 -0.04 -0.01
Nausea
I become sick to 
my stomach 
when I have 
medical 
treatments
0.46 -0.16 0.16 -0.02 0.00 0.34 -0.02 0.88 0.05 -0.05 -0.05 0.04
Food does not 
taste very good 
to me
0.79 0.10 -0.04 -0.02 0.01 -0.02 -0.01 0.83 0.04 0.10 -0.15 0.02Sato et al. Health and Quality of Life Outcomes 2010, 8:38
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I become sick to 
my stomach 
when I think 
about medical 
treatments
0.61 -0.06 0.01 -0.01 0.11 0.20 0.08 0.80 0.06 -0.04 -0.01 0.00
I feel too sick to 
my stomach to 
eat
0.80 0.06 -0.14 -0.02 0.22 -0.14 -0.01 0.88 -0.04 -0.01 0.05 0.04
Some foods and 
smells make me 
sick to my 
stomach
0.96 -0.03 0.00 0.04 -0.26 -0.16 0.01 0.86 -0.04 0.04 0.10 -0.04
Worry
I worry about side 
effects from 
medical 
treatments
0.30 -0.06 0.25 0.06 0.33 -0.04 -0.05 0.25 0.02 0.02 0.72 0.04
I worry about 
whether or not 
my medical 
treatments are 
working
0.00 -0.01 0.13 0.10 0.65 0.08 -0.07 0.01 0.02 0.05 0.92 -0.03
I worry that my 
cancer will come 
back or relapse
-0.02 0.00 0.06 0.06 0.79 -0.05 0.12 -0.16 -0.06 -0.08 0.81 0.01
Factor patterns from a principal factor method with promax rotation. Factor loadings of more than 0.30 are bolded.
Table 4: Factorial validity of the Japanese version of the PedsQL™ Brain Tumor Module (Continued)
Balance scale for the child-report was excluded from the
original version [16]. Previous studies have shown that
problems with movement and balance are important but
infrequent in children with brain tumors [4,29]. Although
the ceiling effect was relatively high, our version pre-
sented score distributions for the child-report including
the Movement and Balance scale, which has a standard
deviation nearly equal to that of the other scales. With
regard to the Pain and Hurt scale, we observed a narrow
range and low standard deviation, due in large part to the
characteristics of our sample population. Because more
than one month had passed since the children's histologi-
cal diagnosis of a brain tumor, a few children who took
part in our study were experiencing pain from intracra-
nial hypertension or postoperative pain.
Several studies have reported on the differences and
concordance between the child- and parent-reports. The
differences between these reports are dependent on the
scales and samples [30,31]. In the present study, scores for
all child-report scales were higher than those for the par-
ent-report. Good concordance has been reported for
observable domains such as physical activity or symp-
toms, while poor concordance has been reported for non-
observable domains such as depression or social quality
of life [32-34]. In the present study as well, good concor-
dance was observed for the Movement and Balance scale,
the Procedural Anxiety scale, and the Nausea scale, while
poor concordance was observed for the Worry scale,
findings which suggest that using the PedsQL™ Brain
Tumor Module with both the child- and parent-reports
can provide bilateral information. In this manner, we rec-
ommend interpretation of both aspects of HRQOL based
on the child- and parent-reports.
With regard to obtention of results, only a short
amount of time was required to complete the question-
naire, and few missing values were observed, suggesting
good feasibility. With regard to children of any age with
impairments who were unable to complete their ques-
tionnaires on their own (in the present study, those with
mental retardation, attention deficit disorder, dyslexia,
visual impairment, and paresis), interviewer-delivered
administration has been found to help these participants
complete the child-report questionnaires. Given that
these children made up a non-negligible percentage of
our population (17%), the importance of participants hav-
ing access to interviewer-administration cannot be over-
stated. Although severe mental retardation hampered
one child from completing the child-report questionnaire
even with an interviewer's assistance, the child's parents
had no problems in completing the parent-report. Persis-
tent disturbance of consciousness in her child hampered
one parent from completing the parent-report question-
naire. With regard to the applicable scope of the PedsQL™
Brain Tumor Module, the present findings suggest that
this module can be used even on children with severe
mental retardation, although not on children with persis-
tent disturbance of consciousness.Sato et al. Health and Quality of Life Outcomes 2010, 8:38
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Table 5: Known-groups validity of the Japanese version of the PedsQL™ Brain Tumor Module
Child-report Parent-report
Number of 
patients 
(n)
Mean SD Difference 95% CI
(P)a
Number 
of 
patients 
(n)
Mean SD Difference 95% CI
(P)a
Cognitive 
Problems
Have received 
whole brain 
irradiation
Yes 54 66.4 23.6 5.3 -2.3 12.9 56 59.1 22.4 8.4 0.8 16.0
No 83 71.7 20.7 (0.168) 84 67.5 22.3 (0.031)
Experiencing 
developmental 
impairment
Yes 27 57.1 26.7 15.5 6.5 24.5 28 42.2 22.9 27.4 19.1 35.7
No 110 72.7 19.6 (< 0.001) 112 69.6 19.0 (< 0.001)
Movement 
and Balance
Tumor location
Infratentor
ial
52 74.7 29.0 15.0 6.6 23.4 67 57.0 28.0 23.2 14.7 31.7
Supratento
rial
79 89.7 19.8 (< 0.001) 93 80.2 26.1 (< 0.001)
Experiencing 
paresis of 
hands or legs
Yes 28 57.7 32.6 32.9 24.2 41.6 35 33.6 24.6 46.7 38.3 55.1
No 108 90.7 16.4 (< 0.001) 131 80.3 21.7 (< 0.001)
Nausea
Currently 
undergoing 
chemotherapy
Yes 36 72.1 29.4 18.7 11.2 26.3 46 62.6 27.9 30.0 23.6 36.4
No 100 90.8 14.7 (< 0.001) 118 92.6 13.6 (< 0.001)
aP-value from Student's t test
CI, confidence interval
In addition to good feasibility, our results also sug-
gested sufficient reliability. All scales for both the child-
and parent-reports showed retest reliability. With regard
to child-report scales, although agreement for the Pain
and Hurt scale between the initial test and retest was rela-
tively low compared to that observed for other scales, val-
ues were not lower than those for other scales in a
systematic review on assessment of pediatric pain [35].
Most scales for the child-report and all scales for the par-
ent-report showed internal consistency reliability coeffi-
cients approaching or exceeding the standard of 0.70. For
the Pain and Hurt scale for the child-report in particular,
the narrow range may result in a lower Cronbach's coeffi-
cient alpha. Scales not approaching or meeting the 0.70
standard should be used only for descriptive or explor-
atory research.
Additionally, proof of the validity of our results was evi-
denced on several points. The fixed scale-development
methods of the present study ensured the content validity
and the results ensured construct validity through facto-
rial, known-groups, and convergent and discriminant
validity. Our study was the first to clarify the module's
factor structure, which had not been confirmed in the
original version or other translations of the PedsQL™
Brain Tumor Module. Each scale was sensitive for medi-
cal variables and treatment status within the scope of the
assumption. The 95% confidence interval of the Cognitive
Problems scale for the child-report with regard to having
undergone whole brain irradiation spanned across zero.
Variations in age at undergoing radiation and time since
radiation treatment in our sample might reduce between-
group differences. In addition to whole brain irradiation,Sato et al. Health and Quality of Life Outcomes 2010, 8:38
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Table 6: Convergent and discriminant validity of the Japanese version of the PedsQL™ Brain Tumor Module
The PedsQL™ Generic Core Scales STAIC
Physical 
Functioning
Emotional 
Functioning
Social 
Functioning
School 
Functioning
State Anxiety Trait Anxiety
Child-report (n = 134) (n = 106)
Cognitive 
Problems
0.61 0.56 0.62 0.70 -0.45 -0.51
Pain and 
Hurt
0.46 0.62 0.47 0.43 -0.34 -0.54
Movement 
and 
Balance
0.77 0.49 0.69 0.61 -0.17 -0.31
Procedural 
Anxiety
0.50 0.53 0.52 0.52 -0.21 -0.41
Nausea 0.57 0.42 0.32 0.38 -0.29 -0.14
Worry 0.50 0.59 0.44 0.44 -0.39 -0.42
Parent-report (n = 166)
Cognitive 
Problems
0.43 0.43 0.57 0.79
Pain and 
Hurt
0.50 0.52 0.20 0.54
Movement 
and 
Balance
0.76 0.52 0.52 0.48
Procedural 
Anxiety
0.37 0.38 0.18 0.28
Nausea 0.35 0.50 0.02 0.30
Worry 0.21 0.53 0.30 0.28
STAIC, the State-Trait Anxiety Inventory for Children
other factors related to cognitive function exist, such as
intracranial surgery [5] and hydrocephalus [36], and con-
sideration of these factors may be recommended in clini-
cal investigations into cognitive problems. All scales have
been confirmed to correlate better with theoretically pre-
dicted scales than with the non-predicted scales, albeit by
a trivial difference. We were not surprised by our obser-
vation of correlations between non-predicted pairs,
because all scales of PedsQL™ Brain Tumor Module and
PedsQL™ Generic Core Scales are domains of HRQOL.
One limitation to our study warrants mention. Our
sample population did not include children with tumors
diagnosed less than one month prior to administration of
the questionnaire, which may limit the generalizability of
the findings. Future studies and analyses are needed to
explore the sensitivity and responsibility of the PedsQL™
Brain Tumor Module and factors related to the child-par-
ent discordance for the Worry scale.
Conclusions
We developed the Japanese version of the PedsQL™ Brain
Tumor Module and confirmed its feasibility, reliability,
and validity. This module is the only validated instrument
suitable for evaluating brain tumor-specific HRQOL in
children. High feasibility may decrease loss of patients to
follow-up even in prospective studies. Using this module
to assess primary and secondary endpoints may be useful
in enabling future studies to become more sensitive to the
interplay of disease- and treatment-specific effects. Fur-
ther, descriptive or exploratory studies can identify high-
risk groups of children with tumors as well as survivors of
brain tumors, and thereby develop nursing intervention
regimens based on individual risk level. Use of the Ped-
sQL™ Brain Tumor Module in clinical trials and studies
may help to improve HRQOL in children with brain
tumors.Sato et al. Health and Quality of Life Outcomes 2010, 8:38
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